Paolo Tarantino: Happy to have worked with Sarah Sammons and Nancy Lin at the ph2 DATO-Base trial
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared a post by Sarah Sammons, Breast Medical Oncologist at the Dana-Farber Cancer Institute, on X/Twitter:
“One of the most impactful aspects about Antibody Drug Conjugates (ADCs) is their remarkable intracranial activity, seen with T-DM1 and T-DXd. No data is however available with Trophoblast cell surface antigen 2 (TROP2) ADCs.
Happy to have worked with Sarah Sammons and Nancy Lin at the ph2 DATO-Base trial of Dato-DXd for brain metastasis, now open at Dana-Farber Cancer Institute!”
Quoting Sarah Sammons’s post:
“Paolo Tarantino, Nancy Lin and I’s Investigator Sponsored Trial (IST) evaluating the efficacy of datopotamab deruxtecan in active breast cancer brain metastases and Leptomeningeal Disease (LMD) is open with 1st patient screened.”
Read further.
Source: Paolo Tarantino/X and Sarah Sammons/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023